A B S T R A C T We have studied the transport of alphaaminoisobutyric acid (AIB) -3-"C and its response to cortisol and cycloheximide in vitro in blood lymphocytes from untreated patients with chronic lymphocytic leukemia. The accumulation of AIB-3-14C increased in a linear fashion for 60 min, and reached an apparent steady state in 120 min. The initial rate of AIB accumulation (V0) varied from 1.1 to 10.2 /moles/kg cell H20 per min in cells from 16 different patients; however, V. was reproducible in cells from five of six patients which were studied repeatedly over 1-9 months, and correlated positively with the lymphocyte count (r = 0.51, P= < 0.01).
INTRODUCTION
Although the manifestations of chronic lymphocytic leukemia vary greatly from patient to patient, cellular factors which contribute to this variation are poorly understood. A mounting body of evidence indicates that variations in the behavior of many types of mammalian cells are accompanied by significant alterations in plasma membrane function. Transport of certain free amino acids increases during periods of cell proliferation and heightened cell activity, and diminishes progressively with aging and with decreases in rates of growth (1) (2) (3) (4) (5) (6) (7) (8) (9) . These observations suggest that an investigation of plasma membrane function might yield important information about the biological behavior of leukemic lymphocytes. In addition, the toxic effect of adrenal glucocorticoids on leukemic lymphocytes (10) which appears to underlie their therapeutic effectiveness in leukemic patients, may stem in part from modifications in plasma membrane function. Glucocorticoids have been found to impair the transport of a variety of substances, including free amino acids, in lymphoid cells obtained from experimental animals (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) .
In the present study, we examine the characteristics of amino acid transport in human leukemic lymphocytes, and its variation in cell populations from different patients, and from the same patient at different times, using the nonmetabolizable amino acid alpha-aminoisobutyric acid (AIB).' We also examine the effect of cortisol on AIB transport in order to determine the degree to which cortisol inhibits transport processes in human leukemic lymphocytes, and to explore the mechanism of this inhibition.
METHODS
Lymphocyte isolation. Venous blood was obtained from untreated subjects with chronic lymphocytic leukemia and the blood was anticoagulated with sodium heparin (14 U/ ml). White cell and differential counts were performed and the leukocytes isolated after sedimentation of the red cells. 4 vol. of blood was added to 1 vol of 4.0% polyvinylpyrrolidone (PVP) in Hanks's balanced salt solution (HBSS) and incubated at room temperature for 90 min. The supernate was removed and centrifuged for 5 min at 950 g in a Sorvall RC-3 General Purpose Centrifuge (Ivan Sorvall, Inc., Norwalk, Conn.) at 20C. The cells were suspended in HBSS, centrifuged at 950 g and resuspended in HBSS at a final concentration of 1.0-1.2 X 108 lymphocytes/ml. Red cell contamination was less than 8% as determined by counting 300 cells with a phase contrast microscope. Over 95%o of leukocytes were lymphocytes.
Incubation conditions for AIB uptake. Lymphocyte suspensions were added in 0.4 ml portions to flasks containing 2 ml of HBSS with 0.05%o albumin (four times recrystallized), or 2 ml of 20%o (v/v) autologous or isologous plasma in HBSS, yielding a final concentration of 1.7-2.0 X 10' lymphocytes/ml. Isologous plasma was obtained from healthy donors of red cell type AB. Cell suspensions were incubated at 370C in a Dubnoff incubator and shaken at 10 cycle/min in air. Cortisol was added as a solution in absolute ethanol so that the final ethanol concentration was 0.04% (v/v). Untreated cell suspensions received an identical amount of ethanol. AIB, cortisol, and cycloheximide were added at times and in concentrations warranted by each experiment. At termination, the contents of each flask were transferred to cooled 2-ml conical centrifuge tubes (Kimax, Owens-Illinois, Inc., Toledo, Ohio) and sedimented at 950 g for 45 sec at 20C. The supernate was decanted immediately, the side of each tube was dried, and the surface of the pellet was blotted with a thin strip of filter paper. The cell pellet was digested by incubation overnight in a National incubator (National Appliance Co., Portland, Oreg.) at 370C in 0.5 ml of 0.3 M potassium hydroxide (KOH). iA ml of KOH digest was added to 10 ml of Bray's solution (23) and its total radioactivity determined in a Packard liquid scintillation spectrometer (Packard Instrument Co., Inc., Downer's Grove, Ill.). ,gM, and the incubation was continued for an additional 10-180 min. The data represent distribution ratios of AIB-3-"C (A1/Ao) at each time point. Longer periods of labeling (e.g. 180 min) were necessarily associated with longer periods of exposure (e.g. 420 min) to cortisol. These experimental conditions would not be expected to cause a greater degree of inhibition than that seen in cells which were treated for a shorter period of time, since cortisol inhibition appears to be maximal in 34 hr (see Fig. 5 ).
Corp., Boston, Mass., and cycloheximide from Sigma Chemical Co., St. Louis, Mo. Statistical methods. Means, variances, correlation coefficients, coefficients of variation, and regression lines were calculated by standard formulas.
RESULTS
Initial rates and equilibrium values of AIB transport in untreated and cortisol-treated leukemic lymphocytes. The accumulation of AIB by leukemic lymphocytes increased in linear fashion for the first 60 min of exposure to AIB-3-14C and reached an apparent steady state in 120 min (Fig. 1) . In order to compare AIB transport in leukemic lymphocytes from different patients, we examined initial rates of AIB accumulation (V.), which were calculated from the amount of AIB-3-14C accumulated during the first 20 min of exposure to AIB, after a preliminary incubation for 4 hr without added AIB. These studies revealed marked variation in the magnitude of VO between cell populations from 16 patients (Table I) , but little variation among quadruplicate samples from the same cell population (Table I legend). The source of plasma added to the incubation medium did not influence the rate of AIB accumulation.
VO was virtually constant in cells from the same patient incubated in medium containing isologous plasma from each of several different sources, or in autologous plasma (data not shown). There was a significant positive correlation (r = 0.51, P < 0.01) between VO and the lym- Table I . Cells from patient A. B. were distributed into 50-ml Erlenmeyer flasks containing 25 ml of incubation medium, with or without cortisol, 10 AsM. After incubation for 180 min, AIB-3-14C was added to each cell suspension so that its concentration in the medium was 3.3 icM, and the incubation continued for an additional 120 min. The reduced concentration of AIB was used so as to obtain steady-state cellular AIB concentrations which approximated those seen after 20 min of exposure to AIB-3-14C. Cells from each flask were harvested by centrifugation, and resuspended in AIBfree medium at 370C with or without cortisol according to their treatment during the initial period of incubation. The resuspended cells were transferred to new 50-ml flasks, and incubated for 20 min. 2-ml portions of each cell suspension were removed at the start of the incubation, and every 5 min thereafter, and the cellular concentration of AIB-3-14C was estimated as described under Methods. The data are given as distribution ratios of AIB-3-14C (At/Ao) at each point in time.
Treatment with 10 AM cortisol for 4 hr reduced the initial rate of AIB accumulation (V.) in cells from 16 patients by a mean of 43.4±4.1% (SE) . A statistically significant (P < 0.05) reduction appeared in cells from 15 of 16 patients (Table I) . Cortisol was found to inhibit VO and the apparent steady-state accumulation of AIB to the same degree (Fig. 1) .
The fact that cortisol decreased the initial rate of accumulation suggests that it inhibited the uptake of AIB, since exodus would not be expected to modify net AIB accumulation appreciably during this period. This interpretation was substantiated by the failure of cortisol to enhance the exodus of AIB from cells which had been exposed to AIB-3-14C for 180 min before transfer to a medium free of AIB (Fig. 3) . The fractional turnover rate (FTR) of AIB-3-14C was calculated by the formula (ln (AIB) t -In (AIB) t2)/(ts-ti), where ti = zero time and to= 20 min. The FTR of AIB from cortisol-treated cells was less (0.0069) than that of control cells (0.0099); however, this difference was accounted for by the higher gradient for exodus in control cells. Initial pool size (concentration) of AIB was 48% greater and FTR 43% greater in control as compared with cortisol-treated cells. These data indicate that the inhibition of AIB accumulation by cortisol at apparent steady state is not explained by an acceleration of exodus.
Reproducibility of AIB accumulation and of sensitivity to cortisol. Since the magnitude of V0 and cortisol inhibition varied over a wide range in different populations of leukemic cells, we studied cells from the same patients at different times over a 9 month period to determine the reproducibility of amino acid accumulation and cortisol sensitivity. Little variation in VO was seen on the numerous occasions when an individual patient was studied on successive days or weeks, suggesting that the differences in VO between patients did not stemq from experimental variation. There was a small to moderate degree of variation in VO in cells from five of six patients (W. F., G. B., M. M., V. S., and L. K.) restudied at longer intervals (Table II) , and marked variation in one patient (A. B.). The degree of cortisol inhibition did not vary appreciably in cells from five patients studied at different times (G. B., V. S., M. M., A. B., and L. K.) and varied greatly in one patient (W. F.).
Effects of cortisol on the kinetic parameters of active AIB transport and on transport which is apparently non- To determine whether cortisol inhibits nonsaturable as well as saturable uptake of AIB, cortisol-treated and untreated lymphocytes were labeled with a concentration of AIB (20 mM) at which apparent nonsaturable uptake accounts for 80% of AIB accumulation over the 20 min of study (see Fig. 4 for Vm..). Cortisol had no effect on the accumulation of AIB under these conditions (Table  III) suggesting that its action is limited to the saturable mechanism for AIB transport.
Time-course, dose-response relationships, and persistence of cortisol effect. Glucocorticoids are known to inhibit the uptake of free amino acids in rat thymic lymphocytes -in vitro (19) (20) (21) (22) . This inhibition appears to arise indirectly, since it develops at low steroid concentrations, is delayed in onset, depends on continued protein synthesis, and persists after treated cells are transferred to steroid-free medium (19) (20) (21) (22) . To determine whether cortisol inhibits AIB uptake in human leukemic lymphocytes by a similar indirect mechanism, we examined the time of onset and disappearance of cortisol inhibition and its dose-response relationships. No statistically significant effect was produced by 1 hr of treatment in any of the four patients studied (Fig. 5) 10 Mm, and were exposed to AIB-3-4C during the final 20 min of this period. Various AIB concentrations were achieved by adding an appropriate amount of nonradioactive AIB and a constant amount of AIB-3-_1C to the cell suspensions. The experimentally observed points were found to satisfy the assumption of linearity required for linear regression analysis which was used to obtain equations defining the two lines. The data for untreated cells are the composite of two separate experiments performed at a 30 day interval. These experiments produced virtually identical kinetic parameters for AIB-3-14C accumulation.
at that time and at 3 hr in all patients. In order to determine whether established cortisol inhibition persisted in the absence of steroid, we examined AIB uptake in lymphocytes which had been treated for 180 min and then transferred to steroid-free medium. Marked inhibition of AIB accumulation persisted for 60 min after Lymphocytes from patient G. B. were treated and incubated with AIB-3-14C as described in Table I . AIB-3-14C was diluted with nonradioactive AIB before addition in order to achieve a concentration of 20 mm. Each value represents the mean ±SE of quadruplicate determinations of V0 (micromoles/ kilogram cell H20 per minute). Table LI. transfer in lymphocytes from two patients (54 and 47%, respectively). In studies with two separate patients, the degree of inhibition of AIB uptake was directly related to the starting concentration of cortisol (Fig. 6) . Moreover, as little as 0.1 FuM cortisol was inhibitory in cells from one patient (A. B.). Effects of cycloheximide on AIB transport and its inhibition by cortisol. Cycloheximide, a potent inhibitor of protein synthesis in lymphoid cells (27) , has been shown to decrease the uptake of AIB in rat thymic lymphocytes (22) , suggesting that labile protein may be involved in the. transport of low molecular weight substrates across the lymphocyte plasma membrane. Hence, cortisol could decrease AIB transport in leukemic lymphocytes by inhibiting the replenishment of such a labile transport protein. Alternatively, cortisol could act by a mechanism which requires de novo protein synthesis (e.g. by inducing the synthesis of a protein which inhibits transport). To differentiate between these possibilities, lymphocytes were incubated in the presence of cycloheximide, cortisol, or both. Treatment with cycloheximide for 4 hr inhibited the transport of AIB to a statistically significant degree in cells from only four of eight patients (Table IV) . Studies performed in parallel (data not shown) revealed that cycloheximide inhibited the incorporation of leucine-1-'4C into protein by more than 95% whether or not it decreased AIB transport. The same results were obtained when one cycloheximidesensitive and one cycloheximide-resistant cell population were studied again (Table IV) . It is of particular interest that the four cell populations which responded to cycloheximide with decreased AIB accumulation had higher rates of AIB transport than any of the nonresponsive populations. Moreover, cycloheximide inhibited AIB accumulation to the greatest degree in cells from DISCUSSION The presence of intrinsic differences in the active mechanism for AIB transport best explains the observed variation in VO among different leukemic lymphocyte populations. Experimental variation, and differences in the extracellular concentrations of other free amino acids and in the rate of protein synthesis do not appear to account for these differences, since VO was quite reproducible in cells from the same patient at different times and incubated in plasma from different sources, and was not altered by cycloheximide in some cell populations. The fact that V. could be correlated with the blood lymphocyte count suggests that transport of free amino acids might determine the ability of lymphocytes to proliferate or survive. This possibility is supported by the previous demonstration that an acceleration of AIB transport precedes the proliferation of human lymphocytes induced by phytohemagglutinin in vitro (8) .
The ability of cycloheximide to inhibit AIB transport in some lymphocyte populations provides indirect evidence for the participation of protein with a short halflife in the transport system, as has been proposed in other tissues (e.g. rat diaphragm, thymic lymphocytes, embryonic chick bone [17, [28] [29] [30] [31] the total capacity (V.ax) of the transport system, rather than the affinity (apparent Ki) of the system for AIB. However, these kinetics must be confirmed in studies with additional patients because of the wide variation between patients in rates of AIB transport and cortisol sensitivity.
Cortisol has been found to exert many effects on the metabolism of animal lymphocytes, including inhibition of transport processes (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) , and of macromolecule synthesis (19, 20, 22, 32, 33) and these effects appear to arise indirectly. Studies of Mosher, Young, and Munck (34) and Munck (35) indicate that an initial binding of glucocorticoids to specific nuclear receptors may trigger the de novo synthesis of RNA and protein, and that this protein (or proteins) mediates in an unknown fashion the subsequent inhibitory effects of the hormone.
The inhibitory effect of cortisol on AIB transport in human leukemic lymphocytes may not be related entirely to its glucocorticoid activity, since nonglucocorticoids in high concentration (e.g. 10 lAM progesterone) have been found to exert a similar effect in animal lymphocytes (19) . This would imply that glucocorticoid-specific receptors are not involved in this action of cortisol. However, the response of human lymphocytes to cortisol resembled the glucocorticoid-specific responses of thymic lymphocytes in two ways: sensitivity to low concentrations of hormone (0.1 FIM and 1 lM), and a requirement for de novo protein synthesis. Additional studies with lower cortisol concentrations and with other steroids will be necessary in order to establish the specificity of cortisol action in the human cells.
The wide but reproducible variation in the degree to which cortisol inhibited AIB transport in leukemic lymphocytes from different patients was noteworthy. Each cell population may possess a characteristic sensi-tivity to cortisol, since, in most instances, the effectiveness of cortisol on a given cell population did not change with time. Many factors could participate in determining this sensitivity. One important possibility is that cortisol sensitivity may depend on the number or affinity of cellular receptors. Indeed, mouse lymphosarcoma cells which are resistant to the metabolic effects of glucocorticoids appear to bind less glucocorticoid than hormone-sensitive lymphosarcoma cells (36, 37) .
Glucocorticoids produce a late (3-4 hr) decrease in the incorporation of amino acids and nucleosides into protein and nucleic acids in human leukemic lymphocytes in vitro (38, 39) . Since a shorter period of treatment suffices to inhibit the uptake of free amino acids, these changes in incorporation may result from impaired transport of precursors rather than from direct inhibition of macromolecule synthesis, and thereby represent an alteration in plasma membrane function induced by cortisol.
